News | | More »

Analys Active Biotech: Ny plan för ögonstudie (in Swedish)

Analyses and Presentations

Interim Report Jan-Jun 2021

Interim Reports

Active Biotech’s partner NeoTX will host KOL webinar on overcoming check point Inhibitor resistance

Press Release

Active Biotech provides status update of its clinical naptumomab project

Press Release

Active Biotech’s presentation at ABGSC Life Science Summit May 25 2021

Analyses and Presentations

Annual General Meeting of Active Biotech AB

Press Release

Annual Report 2020 Active Biotech AB (publ)

Annual Reports

Active Biotech and NeoTX announce FDA Clearance of IND for Phase II Clinical Trial of Naptumomab


An Experienced Team with Extensive Knowledge in Drug Development


Clinical Study in Uveitis to Start During 2021


Novel Treatment of the Blood Cancer Multiple Myeloma


We Develop New Treatments for Cancer and Inflammatory Diseases

We leverage our extensive knowledge and previously generated documentation on our assets to develop novel treatments for specialist indications with high medical need and commercial value within cancer and inflammatory eye disorders. We have a stringent focus on our projects in multiple myeloma, uveitis and in solid tumors for naptumomab in partnership with NeoTX.

Novel treatments for specialist indications


Disease Area
Phase I
Phase II
Phase III
Naptumomab Combination with anti-PDL1 (durvalumab) in solid tumors
Naptumomab Combination with docetaxel in Non-small cell lung cancer*
Tasquinimod Multiple myeloma**
Laquinimod Uveitis
Study ongoing
Preclinical activities ongoing
* Study preparations ongoing
** In an academic partnership with the Abramson Cancer Center, Philadelphia, University of Pennsylvania

Our project portfolio comprises small, orally active immunomodulatory molecules as well as antibody-based immunotherapy. We have three projects in our project portfolio, Tasquinimod, Laquinimod and Naptumomab. Read more about Active Biotechs projects »

Uveitis can Lead to Severe Eye Problems Including Blindness


Multiple Myeloma a Blood Cancer with Unmet Medical Need